Total Payments
$1.5M
2024 Payments
$111,978
Companies
59
Transactions
2,047
Medicare Patients
4,997
Medicare Billing
$683,152
Payment Breakdown by Category
Other$890,592 (61.3%)
Research$362,666 (25.0%)
Consulting$136,356 (9.4%)
Travel$35,819 (2.5%)
Food & Beverage$27,529 (1.9%)
Education$399.49 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $851,249 | 695 | 58.6% |
| Unspecified | $362,666 | 300 | 25.0% |
| Consulting Fee | $136,356 | 72 | 9.4% |
| Travel and Lodging | $35,819 | 317 | 2.5% |
| Food and Beverage | $27,529 | 621 | 1.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $21,012 | 14 | 1.4% |
| Honoraria | $14,931 | 4 | 1.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,400 | 2 | 0.2% |
| Education | $399.49 | 22 | 0.0% |
Payments by Type
General
$1.1M
1,747 transactions
Research
$362,666
300 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $466,797 | 719 | $0 (2024) |
| Medtronic MiniMed, Inc. | $163,761 | 184 | $0 (2020) |
| Eli Lilly and Company | $154,073 | 37 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $143,315 | 144 | $0 (2024) |
| Novo Nordisk Inc | $94,729 | 151 | $0 (2024) |
| Medtronic, Inc. | $68,618 | 170 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $65,962 | 90 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $65,852 | 111 | $0 (2024) |
| Amarin Pharma Inc. | $34,142 | 57 | $0 (2023) |
| Senseonics, Incorporated | $26,334 | 15 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $111,978 | 186 | SANOFI-AVENTIS U.S. LLC ($44,184) |
| 2023 | $112,818 | 233 | Lilly USA, LLC ($52,768) |
| 2022 | $166,242 | 227 | Lilly USA, LLC ($62,996) |
| 2021 | $192,365 | 242 | Lilly USA, LLC ($64,445) |
| 2020 | $173,499 | 232 | Lilly USA, LLC ($80,402) |
| 2019 | $209,867 | 315 | Lilly USA, LLC ($56,380) |
| 2018 | $265,012 | 309 | Eli Lilly and Company ($66,448) |
| 2017 | $221,580 | 303 | Lilly USA, LLC ($70,804) |
All Payment Transactions
2,047 individual payment records from CMS Open Payments — Page 1 of 82
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: Obesity | ||||||
| 12/18/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $1.39 | General |
| Category: Durable Pump | ||||||
| 12/13/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: Diabetes | ||||||
| 12/10/2024 | Insulet Corporation | Omnipod (Device) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $500.00 | General |
| Category: Insulin Pump | ||||||
| 12/09/2024 | Medtronic, Inc. | — | Consulting Fee | Cash or cash equivalent | $775.00 | General |
| 12/03/2024 | SANOFI-AVENTIS U.S. LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,096.00 | General |
| 11/26/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,298.00 | General |
| Category: Endocrinology | ||||||
| 11/23/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Food and Beverage | In-kind items and services | $68.90 | General |
| Category: Endocrinology | ||||||
| 11/22/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,915.00 | General |
| Category: Endocrinology | ||||||
| 11/15/2024 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | In-kind items and services | $21.80 | General |
| Category: Endocrinology | ||||||
| 11/14/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,298.00 | General |
| Category: Endocrinology | ||||||
| 11/14/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,258.00 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/13/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,483.00 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/13/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Travel and Lodging | Cash or cash equivalent | $80.40 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/13/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $77.88 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/13/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Travel and Lodging | Cash or cash equivalent | $13.40 | General |
| Category: Endocrinology | ||||||
| 11/08/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: Endocrinology | ||||||
| 11/06/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Travel and Lodging | Cash or cash equivalent | $23.45 | General |
| Category: Diabetes | ||||||
| 11/04/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Diabetes | ||||||
| 11/04/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: Diabetes | ||||||
| 11/03/2024 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $32.78 | General |
| 11/01/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,258.00 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/01/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $34.89 | General |
| Category: Automated insulin delivery system | ||||||
| 10/31/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Diabetes | ||||||
| 10/31/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Food and Beverage | In-kind items and services | $111.53 | General |
| Category: Endocrinology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | Eli Lilly and Company | $59,503 | 4 |
| HCL Pediatrics | Medtronic MiniMed, Inc. | $54,060 | 25 |
| CEP 304 670G Outcomes Study | Medtronic MiniMed, Inc. | $39,825 | 37 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO, BOTH IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC IN ADULTS WITH TYPE 2 DIABETES PRONTO-T2D | Eli Lilly and Company | $31,346 | 3 |
| CIP321 AHCL Pivotal Study | Medtronic, Inc. | $24,868 | 41 |
| A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN GLARGINE IN ADULTS WITH TYPE 2 DIABETES ON MULTIPLE DAILY INJECTIONS | Eli Lilly and Company | $17,590 | 1 |
| CEP302 HCL Pediatrics | Medtronic MiniMed, Inc. | $16,300 | 11 |
| CEP298 EWIS | Medtronic MiniMed, Inc. | $15,600 | 12 |
| A PHASE 2 STUDY OF ONCE-DAILY LY3502970 COMPARED WITH PLACEBO IN PARTICIPANTS WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | Eli Lilly and Company | $11,381 | 4 |
| CEP304 HCL Outcomes Study | Medtronic, Inc. | $10,273 | 24 |
| CEP294 HCL | Medtronic MiniMed, Inc. | $9,890 | 21 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $9,427 | 3 |
| CIP321 AHCL Pivotal Study | Medtronic MiniMed, Inc. | $7,510 | 16 |
| A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 1 DIABETES TREATED WITH MULTIPLE DAILY INJECTION THERAPY | Eli Lilly and Company | $7,425 | 1 |
| CIP336 Fiasp | Medtronic, Inc. | $5,583 | 15 |
| A Randomized, Multicenter, Open-Label, Parallel-Group Clinical Study Comparing the Safety and Efficacy of MYL-1601D With NovoLog in Type 1 Diabetes Mellitus Patients; Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus in Type 1 Diabetes Mellitus (T1DM) Patients | Mylan Inc. | $5,525 | 1 |
| CIP335 Lyumjev | Medtronic, Inc. | $5,283 | 16 |
| CIP337 SUCCEED | Medtronic, Inc. | $4,478 | 13 |
| A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $3,896 | 3 |
| A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN STUDY PARTICIPANTS WITH TYPE 1 DIABETES MELLITUS PREVIOUSLY TREATED WITH MULTIPLE DAILY INJECTION THERAPY | Eli Lilly and Company | $3,858 | 1 |
| SMILE | Medtronic MiniMed, Inc. | $3,850 | 8 |
| CIP331 Smart Pen | Medtronic, Inc. | $2,910 | 7 |
| CEP287 TS Peds in Home | Medtronic MiniMed, Inc. | $2,400 | 3 |
| CEP266 ASPIRE Post Market | Medtronic MiniMed, Inc. | $2,150 | 5 |
| CIP324 Zeus Pivotal | Medtronic MiniMed, Inc. | $1,760 | 5 |
| CIP318 Unity Feasibility | Medtronic MiniMed, Inc. | $910.00 | 4 |
| A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | Eli Lilly and Company | $600.01 | 1 |
| China Guardian Connnect | Medtronic MiniMed, Inc. | $600.00 | 2 |
| CIP326 PCL Feasibility | Medtronic MiniMed, Inc. | $585.00 | 2 |
| CEP249 Enlite Ped FU | Medtronic MiniMed, Inc. | $450.00 | 1 |
| CIP344 SUCCEED2 | Medtronic, Inc. | $450.00 | 2 |
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | Eli Lilly and Company | $440.00 | 1 |
| CEP302 HCL Pediatrics | Medtronic, Inc. | $375.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | Eli Lilly and Company | $298.02 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | Eli Lilly and Company | $298.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $285.00 | 1 |
| CIP330 Synergy | Medtronic MiniMed, Inc. | $250.00 | 1 |
| CEP249 Enlite Ped. FU | Medtronic MiniMed, Inc. | $225.00 | 1 |
| CIP338 InPen | Medtronic, Inc. | $210.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 1,094 | 1,995 | $423,771 | $151,460 |
| 2022 | 7 | 1,280 | 2,383 | $508,845 | $183,863 |
| 2021 | 8 | 1,333 | 2,435 | $520,330 | $191,032 |
| 2020 | 9 | 1,290 | 11,166 | $496,770 | $156,797 |
Total Patients
4,997
Total Services
17,979
Medicare Billing
$683,152
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 836 | 1,492 | $358,080 | $134,140 | 37.5% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 145 | 302 | $30,200 | $7,499 | 24.8% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 80 | 82 | $24,026 | $6,947 | 28.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $5,093 | $1,911 | 37.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 22 | 108 | $6,372 | $963.04 | 15.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 936 | 1,766 | $423,840 | $159,444 | 37.6% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 118 | 121 | $35,453 | $10,562 | 29.8% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 147 | 314 | $31,400 | $8,136 | 25.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 17 | $5,474 | $2,242 | 40.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 28 | 29 | $4,582 | $1,933 | 42.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 25 | 124 | $7,316 | $1,259 | 17.2% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 11 | 12 | $780.00 | $287.90 | 36.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 930 | 1,748 | $419,520 | $161,403 | 38.5% |
| 76536 | Ultrasound of head and neck | Office | 2021 | 125 | 126 | $36,918 | $11,175 | 30.3% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 137 | 292 | $29,200 | $7,803 | 26.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 70 | 73 | $11,534 | $4,509 | 39.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 13 | 13 | $6,019 | $2,193 | 36.4% |
| 10005 | Fine needle aspiration of first lesion using ultrasound guidance | Office | 2021 | 19 | 19 | $7,391 | $2,057 | 27.8% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 27 | 152 | $8,968 | $1,563 | 17.4% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2021 | 12 | 12 | $780.00 | $328.44 | 42.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 895 | 1,683 | $403,920 | $130,061 | 32.2% |
| 76536 | Ultrasound of head and neck | Office | 2020 | 102 | 104 | $30,472 | $8,744 | 28.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 111 | 125 | $19,750 | $6,535 | 33.1% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2020 | 106 | 232 | $23,200 | $6,493 | 28.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 14 | 14 | $5,180 | $1,627 | 31.4% |
About Dr. Thomas Blevins, M.D
Dr. Thomas Blevins, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1114992088.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Blevins, M.D has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $111,978 received in 2024. These payments were reported across 2,047 transactions from 59 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($851,249).
As a Medicare-enrolled provider, Blevins has provided services to 4,997 Medicare beneficiaries, totaling 17,979 services with total Medicare billing of $683,152. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Austin, TX
- Active Since 02/22/2006
- Last Updated 01/06/2011
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1114992088
Products in Payments
- TRULICITY (Drug) $133,526
- MOUNJARO (Drug) $112,813
- JARDIANCE (Drug) $107,051
- Minimed 670G System (Device) $73,466
- HUMULIN (Drug) $62,376
- FARXIGA (Drug) $55,339
- SOLIQUA (Drug) $45,160
- TZIELD (Biological) $45,109
- Ozempic (Drug) $41,415
- Vascepa (Drug) $34,142
- Eversense (Device) $26,334
- RYBELSUS (Drug) $25,282
- INVOKANA (Drug) $23,245
- Repatha (Biological) $19,331
- MACRILEN (Drug) $17,015
- MINIMED 670G (Device) $16,066
- BASAGLAR (Drug) $15,837
- Rybelsus (Drug) $15,537
- TOUJEO (Drug) $14,381
- DEXCOM G7 GSS (161) (Medical Supply) $13,917
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Austin
Michele Mcdermott, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $137,974
Endocrinology, Diabetes & Metabolism $137,974
Tira Chaicha-Brom, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $56,872
Endocrinology, Diabetes & Metabolism $56,872
Dr. Simona Scumpia, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $52,573
Endocrinology, Diabetes & Metabolism $52,573
Dr. Padma Horvit, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $20,822
Endocrinology, Diabetes & Metabolism $20,822
Farheen Yousuf, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $9,161
Endocrinology, Diabetes & Metabolism $9,161
Luis Casaubon, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $8,976
Endocrinology, Diabetes & Metabolism $8,976